Jackfruit latex gel with simvastatin induces osteoinduction in human stem cells
The PUC-SP team engineered a jackfruit-latex mucoadhesive gel delivering pomegranate extract and simvastatin that promoted osteoinduction in human stem cells within two to three weeks. In vitro data support localized bone regeneration potential for periodontitis but lack in vivo efficacy and safety metrics. Further animal models are needed to establish clinical translation thresholds.
Researchers manually harvested and purified jackfruit latex, blended it with pomegranate peel extract for antimicrobial action, and loaded simvastatin to create a mucoadhesive matrix intended for direct periodontal pocket delivery. Physicochemical characterization confirmed stability across the three statin concentrations while in vitro assays tracked alkaline phosphatase activity and mineral deposition in adipose-derived stem cells. This local-delivery approach sidesteps first-pass hepatic clearance that limits oral simvastatin bioavailability and raises myopathy risk at higher systemic doses. The design draws on prior work showing simvastatin's pleiotropic effects on osteoblasts and latex's documented adhesive properties in other biomedical contexts, yet extends them to a multi-component periodontitis scaffold.
Contextual analysis reveals the material addresses two persistent gaps in periodontal regeneration: insufficient residence time of topical agents and inconsistent bone regrowth with guided tissue membranes. Earlier animal studies of simvastatin-loaded chitosan gels reported modest attachment gains but suffered rapid clearance; jackfruit latex's natural tackiness may extend contact without synthetic polymers. Still, the absence of microbial challenge or inflammatory cytokine assays leaves open whether the gel suppresses Porphyromonas gingivalis or modulates IL-6/TNF-alpha in diseased tissue.
Next steps require in vivo validation in ligature-induced periodontitis models to quantify bone volume via micro-CT and clinical attachment level changes against standard scaling and root planing. Dose-response refinement and long-term degradation kinetics will determine whether 0.6% simvastatin emerges as the optimal balance of osteoinduction and cytotoxicity before any human pilot study.
Duek: Rat periodontitis model will show >25% greater bone fill versus controls at 8 weeks using 0.6% simvastatin formulation
Sources (2)
- [1]Primary Source(https://link.springer.com/article/10.1007/s00289-026-XXXX-X)
- [2]Supporting Source(https://pubmed.ncbi.nlm.nih.gov/XXXXX/)